When to Use Cytomel (Liothyronine)
Cytomel should NOT be routinely used for hypothyroidism—levothyroxine monotherapy remains the standard of care. 1 However, there are specific clinical scenarios where liothyronine is appropriate.
FDA-Approved Indications
According to the FDA label, Cytomel is appropriate for 2:
- Myxedema and myxedema coma (starting at 5 mcg daily, titrating by 5-10 mcg every 1-2 weeks)
- Congenital hypothyroidism (starting at 5 mcg daily in infants)
- Simple non-toxic goiter (starting at 5 mcg daily)
- Radioisotope scanning procedures where rapid induction of hypothyroidism is needed
- Thyroid suppression testing (75-100 mcg/day for 7 days)
- When impairment of peripheral T4 to T3 conversion is suspected
Experimental Use in Persistent Symptoms
For select patients with confirmed overt hypothyroidism who have persistent symptoms despite optimized levothyroxine therapy, a trial of combination LT4/LT3 may be considered as an experimental approach. 3, 4
Prerequisites Before Considering Liothyronine:
Confirm true overt hypothyroidism existed initially - patients without clear biochemical evidence should first trial discontinuation of thyroid hormone 3
Optimize levothyroxine first:
Exclude other causes of symptoms:
When to Consider a Trial:
Only after the above steps are completed and symptoms persist should combination therapy be considered, and only by accredited endocrinologists. 4
- Use LT4/LT3 ratio between 13:1 and 20:1 by weight 4
- Give LT3 in two divided doses daily 4
- Discontinue if no improvement after 3 months 4
- This is shared decision-making; clinicians are not obligated to prescribe if not in patient's best interest 3
Special Populations Requiring Caution
Elderly patients and those with cardiac disease require extreme caution 2:
- Start at 5 mcg daily
- Increase by no more than 5 mcg increments at 2-week intervals
- Risk of precipitating angina, atrial fibrillation, or cardiovascular events
- The rapid onset of action makes liothyronine particularly risky in this population
Contraindications and Warnings
Never use liothyronine for: 1, 2
- Weight loss in euthyroid patients (ineffective and potentially life-threatening)
- Pregnancy or planning pregnancy (Grade B recommendation against LT4/LT3 combinations)
- Treatment of infertility unless accompanied by hypothyroidism
- Obesity treatment
Critical safety considerations:
- Rule out adrenal insufficiency before starting—correct with hydrocortisone first 1
- In severe/prolonged hypothyroidism, supplemental corticosteroids may be necessary 2
- Wide swings in serum T3 levels occur with liothyronine, increasing cardiovascular risk 2
Pediatric Exception
In congenital hypothyroidism with persistent hyperthyrotropinemia despite good levothyroxine compliance, combination therapy may normalize TSH 7, though this requires careful monitoring and further research on long-term neurodevelopmental outcomes.
Key Clinical Pitfalls
- Do not use desiccated thyroid hormone—there is no evidence supporting its use over levothyroxine monotherapy 1
- Available combined preparations have LT4/LT3 ratios <13:1 and are not recommended 4
- Most patients preferring combination therapy for themselves do not actually use it (only 16% of surveyed endocrinologists) 6
- Recent safety data is reassuring—regulated LT3 use shows no increased risk of death or serious adverse outcomes, and may actually show reduced mortality 8
The evidence remains insufficient to support routine combination therapy, with multiple RCTs showing no benefit over levothyroxine monotherapy 3, 9, 4. The 5-10% of patients with persistent symptoms likely reflect factors other than inadequate T3 replacement.